Sarepta Therapeutics (NASDAQ:SRPT) PT Raised to $179.00

Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) had its target price hoisted by Mizuho from $145.00 to $179.00 in a report issued on Friday, Benzinga reports. The firm presently has a “buy” rating on the biotechnology company’s stock. Mizuho’s target price would suggest a potential upside of 36.25% from the stock’s previous close. A number […]

Related Keywords

Ian Michael Estepan ,Bilal Arif ,Mather Group ,Sarepta Therapeutics Company Profile ,Montaga Associates Inc ,Partners Investment Advisory ,Principal Securities Inc ,Sarepta Therapeutics Inc ,Riggs Asset Managment Co ,Securities Exchange Commission ,Barclays ,Cantor Fitzgerald ,Sarepta Therapeutics ,Get Free Report ,Exchange Commission ,Michael Estepan ,Asset Managment ,Cary Street Partners Investment Advisory ,Street Partners Investment Advisory ,Sarepta Therapeutics Daily ,